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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S12coagulopathy) and two patients survived with sequelae. Overall induction
mortality (12 out of 227 - 5.3%) was solely accounted for by infections. He-
modynamic instability and tachypnoea were the only predictors of mortal-
ity, which was independent of laboratory parameters or culture positivity.
Conclusions: Infections were a major cause of morbidity and the sole
cause of mortality in pediatric ALL during induction chemotherapy, in our
series. Around half of the patients had at least one episode of infection;
gram negative organisms are the predominant isolates in blood culture.
Most infections respond well to standard antibiotic regimens and sequelae
in survivors are rare.
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ETIOLOGICAL PROFILE OF SEIZURES IN CHILDREN UNDERGOING
CHEMOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA
C.S. Guruprasad, R. Binitha, Manjusha Nair, T. Priyakumari,
P. Kusumakumary. Regional Cancer Center, Thiruvananthapuram, Kerala,
India
E-mail address: drguruprasadcs@gmail.com (C.S. Guruprasad).
Background: The prevalence of seizures in the ALL population is reported
to vary between 8 and 13%. Not much is known about the etiology, natural
history of these seizure, the risk factors for their recurrence, and the long-
term need for antiepileptic drug (AED) treatment. Also little is known
about the risk of interaction of AED with chemotherapeutic agents, hence
the dose modiﬁcations needed in chemotherapy when on chronic AEDs. A
data regarding the same from Indian population is lacking.
Methods: It was a Prospective descriptive study, conducted at Pediatric
oncology division of Regional Cancer Centre, Thiruvananthapuram. All
children between the age of 0-14years, with no pre-existing neurological
abnormality developing ﬁrst episode of seizure during the period of ALL
chemotherapy were included. All relevant clinical, treatment related and
investigational data were collected prospectively and analyzed.
Results: 28 patients (7.84%) developed seizures out of 357 patients with
ALL during the study period. Majority of seizures occurred in the B-ALL
immunophenotype, HR groups, during induction chemotherapy. 24 pa-
tients (85.7%) presented with generalized seizure with 13 patients (46.4%)
having status epilepticus. The etiological factors identiﬁed included (in
decreasing order of frequency) CVT, meningitis, encephalitis, febrile sei-
zures, SIADH, hypertension, hypoxia, PRES, Mineralizing microangiopathy,
Sepsis, Gliosis, ADEM, CNS leukemia. 16 patients (57.1%) had associated
hyponatremia. CT scan detected cortical venous thrombosis (CVT) in 5
patients (17.8%). Recurrence of seizure [occurred in 12 patients (42.9%)]
was the only factor that reached statistical signiﬁcance when need for
antiepileptic drug prophylaxis was assessed.
Conclusion: Data regarding incidence and etiology of seizures in ALL is
lacking andmajority of studies attribute chemotherapy and / or radiotherapy
as the causewhen a deﬁnitive etiology could not be found. An etiology could
be detected in 92.8% of seizure episodes in our study with majority being
treatment related complication or related to infections. Most of the episodes
occur during induction chemotherapy probably reﬂecting the intensity of
treatment and active disease in the patient. HD MTX was given in a quarter
of children with seizure during ALL chemotherapy, but typical imaging
ﬁnding suggestive of CNS involvement by methotrexate was rare. Multiple
electrolyte abnormalities were a common ﬁnding, stressing the need for
monitoring of electrolytes and keeping them in the normal range during ALL
chemotherapy, to keep neurological morbidity to the minimum. AED pro-
phylaxis was needed in two thirds of patients, with recurrence of seizure
being the most important predictor for requirement of prophylaxis. Per-
manent neurological deﬁcit was present in one ﬁfth of childrenwith seizure,
suggesting the need for a multidisciplinary approach.LM-1_V1.17
CYTOGENETICS IN B CELL ALL
Piali Mandal 1, Anil Kumar 1, Sunita Sharma 2, Jagdish Chandra 1. 1Division
of Pediatric Hematology, Department of Pediatrics, Lady Hardinge Medical
College and Kalawati Saran Children's Hospital, NewDelhi, India; 2Dept of
Pathology, Lady Hardinge Medical College and Kalawati Saran Children's
Hospital, New Delhi, IndiaIntroduction: Chromosomal abnormalities are hallmark of lymphoblastic
leukemia. Cytogenetic studies have identiﬁed numerical and structural
chromosomal abnormalities which have fundamental importance in the
diagnosis, risk stratiﬁcation, monitoring post-transplant bone marrow and
to assign prognosis.
Aim: To report common cytogenetic abnormalities in B cell ALL patients at
our centre.
Methods: Patients of ALL below 18 years of age, since December 2013were
enrolled and treated on ICiCle protocols. G-banding or FISH was done for
common cytogenetic abnormalities such as t(12;21), t(4;11), t(9;22) &
t(1;19).
Results: Over the period of 33 months, 119 cases of ALL (B cell 99, T cell 20)
were started on treatment. Records of 99 patients of B cell ALL were
reviewed for cytogenetics. M:F ratio was 2.41:1. Eighty ﬁve (85.85%) were
between 1-10 year and 14 (14.14%) were above 10 year. Sixteen (16.16%)
were assigned as SR, 65 (65.65%) as IR and 18 (18.18%) as HR. Thirty nine
(39.39%) patients had cytogenetic abnormalities.
Twelve (12.12%) were t(9;22), 18 (18.18%) were t(12;21), 7(7.07%) were
t(1;19) positive respectively. None were t(4;11) positive. Two patient had
hyperploidy and one had del (1)(q25). t(12;21) and t(1;19) had male
preponderance. Among patients with t(9;22), 58.33% were above 10 years
and 58.33% had hyperleukocytosis. All patients with t(1;19) & two with
t(12;21) were assigned as IR & HR respectively.
Conclusion: Translocation t(12;21) was the commonest abnormality.
Frequency of t(9;22) BCR-ABL was higher while frequency of hyperploidy
was lower to that described in western literature.
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AVOIDING CRANIAL RADIOTHERAPY FOR MOST CHILDRENWITH ACUTE
LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTER STUDY OF CNS
OUTCOME
Geeta Mandhani, Manas Kalra, Amita Mahajan. Apollo Center for Advanced
Pediatrics, Indraprastha Apollo Hospitals, New Delhi, India
Background/objective: CNS relapse occurs in 3-8% of children treated
for acute lymphoblastic leukemia (ALL) and poses a major obstacle in
the long-term cure. Prophylactic cranial radiotherapy (pCRT) and
intrathecal chemotherapy (IT) are both known to prevent this compli-
cation. pCRT is increasingly being avoided in this cohort in view of the
known late effects associated with this modality. However, a number of
centers continue to use it for T cell disease and high risk patients. We
hereby report the experience of our center in terms of CNS control of
leukemia by using the strategy of IT alone and a conservative approach
of using pCRT.
Methods: We conducted a retrospective chart review of children with ALL
from age 1- 18 years who took treatment in our unit from October 2002 to
August 2016. The children were treated as per COG protocol which
comprised of dexamethasone in induction for children less than 10 years of
age. High dose methotrexate at 5 gm/m2 for high risk (HR) ALL and at 3
gm/m2 for standard risk (SR) ALL was included in the treatment regimen
from 2009 onwards. A total of 20- 22 doses of IT were given. Children with
CNS leukemia at diagnosis received 18 Gy of CRT and triple IT and others
received only intrathecal methotrexate. T cell immunophenotype was not
a criterion for giving pCRT. Standard protocols for sedation and positioning
were strictly adhered to during IT administration with the ﬁrst IT being
performed only by a consultant.
Results: Study population comprised of 250 consecutive childrenwith ALL
(70.4% were males) with a median age of 7.19 +/- 4.70 years (Range 1- 18
years). The median follow up was 1575 +/- 1424.7 days (Range 6- 5147
days). Patients less than 1 year of age at diagnosis, and those who
continued treatment at another center have been excluded from this
analysis. SR ALL was seen in 126 children (50.4%), 110 had HR (44%) and 14
had very high risk (VHR) disease (5.6%). B-lineage ALL was present in 210
children (84%), 37 had T-lineage ALL (14.8%) and 3 had biphenotypic ALL
(1.2%). Five children had CNS leukemia at diagnosis. pCRT was given to 11
children (4.4%) which included the above 5, 1 with VHR ALL, and an
additional 5 for concerns regarding inability to travel for regular IT during
maintenance. Six children eventually had a CNS relapse (2.4%), 3 of these
had already received pCRT. One other patient had an orbital relapse of
leukemia and 2 had a combined bone marrow and CNS relapse. Only 2
